ScholarIQanswers from OpenAlex

Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden

PaperCitations, authors & open-access status

Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden have?

ScholarIQcitation count

Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden has 22 citations in the OpenAlex counts ScholarIQ stores.

When was Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden published?

ScholarIQyear

Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden has 2011 year in the ScholarIQ index.

What is the open-access status of Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden?

ScholarIQoa status

Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden has bronze oa status in the ScholarIQ index.

What is the DOI of Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden?

ScholarIQdoi

The DOI for Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden is on the source record.

What is the PMID of Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden?

ScholarIQpmid

The PMID for Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden is on the source record.

What is the OpenAlex record for Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden?

ScholarIQopenalex

The OpenAlex for Cost‐effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial